Breast CancerNCT07767305
Efficacy of Kinesio Taping Versus Compression Therapy on Breast Lymphedema Induced by Radiotherapy After Breast-Conserving Surgery
A study testing Routine Care, Kinesio Taping and Compression Therapy in people with Breast Cancer and Breast Lymphedema, run by Tangshan People's Hospital at 1 site in China.
Trial summary
Breast cancer patients often develop breast lymphedema after breast-conserving surgery and radiotherapy, causing swelling, pain, and heaviness that affect quality of life. This study compares two physical therapy approaches-Kinesio Taping and compression therapy-for relieving breast lymphedema. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer, Breast Lymphedema
- What is being tested?
- Routine Care, Kinesio Taping and Compression Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 99 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2025to 26 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of unilateral breast cancer confirmed according to the Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Guidelines and Standards (2024 edition).
- Underwent breast-conserving surgery and completed breast radiotherapy for at least 2 months prior to enrollment; skin toxicity ≤ Grade 1 according to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria.
- Age ≥ 18 years.
- Ultrasound-diagnosed breast lymphedema in at least one quadrant of the affected breast exceeding the following thresholds: upper outer quadrant thickness ≥ 2.5 mm, upper inner quadrant ≥ 3.0 mm, lower outer quadrant ≥ 2.3 mm, lower inner quadrant ≥ 2.6 mm.
- Presence of breast lymphedema symptoms (breast swelling, peau d'orange appearance, redness, positive Stemmer's sign) confirmed by clinical diagnosis.
- Ability to understand and communicate effectively, capable of completing questionnaires.
- Willing to provide written informed consent to participate in the study.
Who cannot join
- Cognitive impairment or communication dysfunction.
- Severe psychological disorders or psychiatric illness.
- Postoperative cancer recurrence or metastasis with serious complications.
- Other causes of breast swelling unrelated to breast cancer.
- Severe liver or kidney disease, cardiovascular disease, deep vein thrombosis, heart failure, lymphangitis, or current antibiotic treatment for cellulitis that would preclude participation.
- Allergy to Kinesio Tape.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Tangshan People's Hospital
Tangshan, Hebei, 063000
shuo wang, +86 18168499773, 2624592433@qq.com
About this study
Official title: A Randomized Controlled Trial Comparing the Efficacy of Kinesio Taping Versus Compression Therapy on Rehabilitation Outcomes in Breast Cancer Patients With Radiotherapy-Related Breast Lymphedema After Breast-Conserving Surgery
Breast cancer patients often develop breast lymphedema after breast-conserving surgery and radiotherapy, causing swelling, pain, and heaviness that affect quality of life. This study compares two physical therapy approaches-Kinesio Taping and compression therapy-for relieving breast lymphedema. Kinesio Taping is an elastic medical tape applied to the breast skin to promote lymphatic drainage; compression therapy uses an adjustable pressure vest to reduce swelling through external pressure. The study will enroll 99 eligible postoperative breast cancer patients, randomly assigned to three groups: one receiving routine care, one receiving routine care plus Kinesio Taping, and one receiving routine care plus compression therapy, with a 6-week intervention period. Assessments will be conducted at baseline, immediately after intervention, and at 3 and 6 months post-intervention to compare changes in swelling, pain, and quality of life among the three groups. This study has been approved by the Medical Ethics Committee of Tangshan People's Hospital (LLKS), and all participants voluntarily participate with signed informed consent.
Read the detailed description
This is a single-center, three-arm, parallel-group randomized controlled trial conducted at the Department of Breast Surgery, Tangshan People's Hospital (RMYY). A total of 99 female patients with unilateral breast cancer who have undergone breast-conserving surgery, completed radiotherapy for at least 2 months, and developed radiotherapy-related breast lymphedema will be enrolled. Participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) routine care (control), (2) routine care plus Kinesio Taping, or (3) routine care plus compression therapy. The intervention period lasts 6 weeks.
Outcome measures include:
Breast skin thickness measured by ultrasound at four quadrants (upper outer, upper inner, lower outer, lower inner), each measured at 35-40 mm from the nipple, with 3 images averaged per location; Lymphedema-related symptoms (pain, swelling, heaviness, tightness) assessed by Visual Analog Scale (VAS), scored 0-10; Breast transverse and vertical diameters measured by cross-measurement method using a non-elastic tape measure; Quality of life assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B) Chinese version (36 items, 5-point Likert scale, total score 0-144); Self-efficacy assessed by the Breast Cancer Survivors Self-Efficacy Scale (BCSES) Chinese version (11 items, 5-point Likert scale, total score 11-55); Anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS) Chinese version (14 items, 7 for anxiety and 7 for depression).
Assessments will be conducted at baseline (T0), immediately post-intervention at 6 weeks (T1), and at 3 months (T2) and 6 months (T3) post-intervention.
Sample size is 33 participants per group (total 99, including 20% attrition allowance). Randomization will be performed using block randomization with a 1:1:1 allocation ratio. Statistical analysis will follow the intention-to-treat principle. Adverse events will be monitored throughout the study and recorded via follow-up logs and WeChat (a Chinese multi-purpose messaging, social media, and mobile payment app developed by Tencent) platform.
The study protocol has been approved by the Medical Ethics Committee of Tangshan People's Hospital (LLKS) (Approval No. RMYY-LLKS-2025304), and all participants will provide written informed consent before enrollment.
- Conditions
- Breast Cancer, Breast Lymphedema
- Being tested
- Routine Care, Kinesio Taping, Compression Therapy
- Keywords
- Kinesio Taping, Compression Therapy, Breast-Conserving Surgery, Breast Lymphedema
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine CareOther
Health education including explanation of breast lymphedema mechanisms and complications; breast and skin care instructions (cleaning with warm water and mild cleanser, avoiding irritants, wearing loose clothing, avoiding sun exposure for 6 months after radiotherapy); lifestyle guidance (high-protein, high-vitamin, low-fat diet, adequate sleep, proper positioning to promote lymphatic drainage); and rehabilitation exercises (range of motion exercises for the affected upper extremity, performed 1-2 times daily, 10-20 minutes per session, over a 6-week period).
Kinesio TapingOther
Elastic therapeutic tape (KT TAPE, 25 cm × 5 cm pre-cut) applied to the affected breast. Prior to application, a 2 cm × 2 cm test tape is applied to the forearm for 24 hours to rule out allergy. The tape is cut into a fan shape with 4 tails, anchored below the clavicle, and applied diagonally around the breast area with no tension on the tails, covering the edematous area without overlapping. Each application is retained for 3 days, followed by 1 day of rest, repeated over a 6-week period. Participants are instructed on proper removal techniques (skin-pressing and rolling methods) to avoid skin damage.
Compression TherapyOther
Adjustable compression vest made of medical-grade material with a modal inner layer, featuring adjustable Velcro straps on the affected side. Pressure is calibrated using a German precision pressure measurement device, with the sensor placed on the lower outer quadrant of the affected breast to maintain pressure at 18-21 mmHg. The vest is worn for 15-18 hours per day (daytime only, not at night) for 6 weeks. Participants are instructed to discontinue use immediately if they experience dyspnea or chest tightness.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | Routine care including health education, breast and skin care, lifestyle guidance, and rehabilitation exercises. Receives: Other: Routine Care |
| Kinesio Taping Group | Experimental | Participants receive routine care (health education, breast and skin care, lifestyle guidance, and rehabilitation exercises) plus Kinesio Taping applied to the affected breast. The tape is applied in a fan-shaped pattern around the breast area, retained for 3 days, followed by 1 day of rest, repeated over a 6-week period. Receives: Other: Kinesio Taping |
| Compression Therapy Group | Experimental | Participants receive routine care (health education, breast and skin care, lifestyle guidance, and rehabilitation exercises) plus compression therapy using an adjustable compression vest. The vest is worn for 15-18 hours per day, with pressure maintained at 18-21 mmHg, over a 6-week period. Receives: Other: Compression Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lymphedema-Related Symptoms (VAS)
Visual Analog Scale (VAS) assessing patient-reported severity of breast pain, swelling, heaviness, and tightness. Each symptom is scored from 0 (no symptom) to 10 (extremely severe).
Measured: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Secondary outcomes (5)
Ultrasound-Measured Breast Skin Thickness
Ultrasound measurement of breast skin thickness at four quadrants (upper outer, upper inner, lower outer, lower inner). Each quadrant is measured at 35-40 mm from the nipple, and three images are captured at each location and averaged.
Measured: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Breast Circumference Measures
Cross-measurement method using a non-elastic tape measure. Transverse diameter (from sternal border to anterior axillary line at nipple level) and vertical diameter (from 4th intercostal space to lower breast border at nipple level) are measured; average diameter calculated. Each location measured twice and averaged.
Measured: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Quality of Life (FACT-B)
Functional Assessment of Cancer Therapy-Breast (FACT-B) Chinese version. Contains 36 items across 5 domains: physical, social/family, emotional, functional, and additional concerns. Each item scored on a 5-point Likert scale; total score ranges from 0 to 144, with higher scores indicating better quality of life.
Measured: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Self-Efficacy (BCSES)
Breast Cancer Survivors Self-Efficacy Scale (BCSES) Chinese version. Contains 11 items, each scored on a 5-point Likert scale from 1 (completely lacks confidence) to 5 (very confident); total score ranges from 11 to 55, with higher scores indicating greater self-efficacy.
Measured: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Anxiety and Depression (HADS)
Hospital Anxiety and Depression Scale (HADS) Chinese version. Contains 14 items: 7 for anxiety and 7 for depression. Each subscale scored: 0-7 = no symptoms, 8-10 = suspected symptoms, 11-21 = definite symptoms. Higher scores indicate greater severity.
Measured: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study start1 Oct 2025
- Primary completion26 Sep 2026 (estimated)
- Study completion26 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Three-arm parallel randomized controlled trial with a 1:1:1 allocation ratio: routine care (control), routine care plus Kinesio Taping, and routine care plus compression therapy.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 99 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tangshan People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, shuo wang, Tangshan People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07767305
- Sponsor's protocol ID
- RMYY- LLKS-2025304
- Status last verified
- Aug 2026
- First submitted
- 7 Aug 2026
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial Comparing the Efficacy of Kinesio Taping Versus Compression Therapy on Rehabilitation Outcomes in Breast Cancer Patients With Radiotherapy-Related Breast Lymphedema After Breast-Conserving Surgery
- ClinicalTrials.gov ID
- NCT07767305
- Acronym / sponsor ID
- RMYY- LLKS-2025304
- Conditions
- Breast Cancer, Breast Lymphedema
- Keywords
- Kinesio Taping, Compression Therapy, Breast-Conserving Surgery, Breast Lymphedema
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 99 participants (estimated)
- Lead sponsor
- Tangshan People's HospitalUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 26 Sep 2026 (estimated)
- Study completion
- 26 May 2027 (estimated)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Breast cancer patients often develop breast lymphedema after breast-conserving surgery and radiotherapy, causing swelling, pain, and heaviness that affect quality of life. This study compares two physical therapy approaches-Kinesio Taping and compression therapy-for relieving breast lymphedema. Kinesio Taping is an elastic medical tape applied to the breast skin to promote lymphatic drainage; compression therapy uses an adjustable pressure vest to reduce swelling through external pressure. The study will enroll 99 eligible postoperative breast cancer patients, randomly assigned to three groups: one receiving routine care, one receiving routine care plus Kinesio Taping, and one receiving routine care plus compression therapy, with a 6-week intervention period. Assessments will be conducted at baseline, immediately after intervention, and at 3 and 6 months post-intervention to compare changes in swelling, pain, and quality of life among the three groups. This study has been approved by the Medical Ethics Committee of Tangshan People's Hospital (LLKS), and all participants voluntarily participate with signed informed consent.
Detailed description
This is a single-center, three-arm, parallel-group randomized controlled trial conducted at the Department of Breast Surgery, Tangshan People's Hospital (RMYY). A total of 99 female patients with unilateral breast cancer who have undergone breast-conserving surgery, completed radiotherapy for at least 2 months, and developed radiotherapy-related breast lymphedema will be enrolled. Participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) routine care (control), (2) routine care plus Kinesio Taping, or (3) routine care plus compression therapy. The intervention period lasts 6 weeks.
Outcome measures include:
Breast skin thickness measured by ultrasound at four quadrants (upper outer, upper inner, lower outer, lower inner), each measured at 35-40 mm from the nipple, with 3 images averaged per location; Lymphedema-related symptoms (pain, swelling, heaviness, tightness) assessed by Visual Analog Scale (VAS), scored 0-10; Breast transverse and vertical diameters measured by cross-measurement method using a non-elastic tape measure; Quality of life assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B) Chinese version (36 items, 5-point Likert scale, total score 0-144); Self-efficacy assessed by the Breast Cancer Survivors Self-Efficacy Scale (BCSES) Chinese version (11 items, 5-point Likert scale, total score 11-55); Anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS) Chinese version (14 items, 7 for anxiety and 7 for depression).
Assessments will be conducted at baseline (T0), immediately post-intervention at 6 weeks (T1), and at 3 months (T2) and 6 months (T3) post-intervention.
Sample size is 33 participants per group (total 99, including 20% attrition allowance). Randomization will be performed using block randomization with a 1:1:1 allocation ratio. Statistical analysis will follow the intention-to-treat principle. Adverse events will be monitored throughout the study and recorded via follow-up logs and WeChat (a Chinese multi-purpose messaging, social media, and mobile payment app developed by Tencent) platform.
The study protocol has been approved by the Medical Ethics Committee of Tangshan People's Hospital (LLKS) (Approval No. RMYY-LLKS-2025304), and all participants will provide written informed consent before enrollment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- Three-arm parallel randomized controlled trial with a 1:1:1 allocation ratio: routine care (control), routine care plus Kinesio Taping, and routine care plus compression therapy.
| Arm | Type | Receives |
|---|---|---|
| Control Group | Active comparator | Other: Routine CareRoutine care including health education, breast and skin care, lifestyle guidance, and rehabilitation exercises. |
| Kinesio Taping Group | Experimental | Other: Kinesio TapingParticipants receive routine care (health education, breast and skin care, lifestyle guidance, and rehabilitation exercises) plus Kinesio Taping applied to the affected breast. The tape is applied in a fan-shaped pattern around the breast area, retained for 3 days, followed by 1 day of rest, repeated over a 6-week period. |
| Compression Therapy Group | Experimental | Other: Compression TherapyParticipants receive routine care (health education, breast and skin care, lifestyle guidance, and rehabilitation exercises) plus compression therapy using an adjustable compression vest. The vest is worn for 15-18 hours per day, with pressure maintained at 18-21 mmHg, over a 6-week period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Diagnosis of unilateral breast cancer confirmed according to the Chinese Anti-Cancer Association Breast Cancer Diagnosis and Treatment Guidelines and Standards (2024 edition).
- Underwent breast-conserving surgery and completed breast radiotherapy for at least 2 months prior to enrollment; skin toxicity ≤ Grade 1 according to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria.
- Age ≥ 18 years.
- Ultrasound-diagnosed breast lymphedema in at least one quadrant of the affected breast exceeding the following thresholds: upper outer quadrant thickness ≥ 2.5 mm, upper inner quadrant ≥ 3.0 mm, lower outer quadrant ≥ 2.3 mm, lower inner quadrant ≥ 2.6 mm.
- Presence of breast lymphedema symptoms (breast swelling, peau d'orange appearance, redness, positive Stemmer's sign) confirmed by clinical diagnosis.
Key exclusion criteria (6 listed)
- Cognitive impairment or communication dysfunction.
- Severe psychological disorders or psychiatric illness.
- Postoperative cancer recurrence or metastasis with serious complications.
- Other causes of breast swelling unrelated to breast cancer.
- Severe liver or kidney disease, cardiovascular disease, deep vein thrombosis, heart failure, lymphangitis, or current antibiotic treatment for cellulitis that would preclude participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Routine CareHealth education including explanation of breast lymphedema mechanisms and complications; breast and skin care instructions (cleaning with warm water and mild cleanser, avoiding irritants, wearing loose clothing, avoiding sun exposure for 6 months after radiotherapy); lifestyle guidance (high-protein, high-vitamin, low-fat diet, adequate sleep, proper positioning to promote lymphatic drainage); and rehabilitation exercises (range of motion exercises for the affected upper extremity, performed 1-2 times daily, 10-20 minutes per session, over a 6-week period). | Other | Control Group |
| Kinesio TapingElastic therapeutic tape (KT TAPE, 25 cm × 5 cm pre-cut) applied to the affected breast. Prior to application, a 2 cm × 2 cm test tape is applied to the forearm for 24 hours to rule out allergy. The tape is cut into a fan shape with 4 tails, anchored below the clavicle, and applied diagonally around the breast area with no tension on the tails, covering the edematous area without overlapping. Each application is retained for 3 days, followed by 1 day of rest, repeated over a 6-week period. Participants are instructed on proper removal techniques (skin-pressing and rolling methods) to avoid skin damage. | Other | Kinesio Taping Group |
| Compression TherapyAdjustable compression vest made of medical-grade material with a modal inner layer, featuring adjustable Velcro straps on the affected side. Pressure is calibrated using a German precision pressure measurement device, with the sensor placed on the lower outer quadrant of the affected breast to maintain pressure at 18-21 mmHg. The vest is worn for 15-18 hours per day (daytime only, not at night) for 6 weeks. Participants are instructed to discontinue use immediately if they experience dyspnea or chest tightness. | Other | Compression Therapy Group |
Primary outcome
Lymphedema-Related Symptoms (VAS)
Time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Visual Analog Scale (VAS) assessing patient-reported severity of breast pain, swelling, heaviness, and tightness. Each symptom is scored from 0 (no symptom) to 10 (extremely severe).
5 secondary outcomes
Ultrasound-Measured Breast Skin Thickness
Time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Breast Circumference Measures
Time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Quality of Life (FACT-B)
Time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Self-Efficacy (BCSES)
Time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Anxiety and Depression (HADS)
Time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Routine Care, Kinesio Taping and Compression Therapy in people with Breast Cancer and Breast Lymphedema, run by Tangshan People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lymphedema-Related Symptoms (VAS) (time frame: Baseline (T0), immediately post-intervention at 6 weeks (T1), 3 months post-intervention (T2), and 6 months post-intervention (T3)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.